Tuesday, September 1, 2026

A Long-Acting Oral Drug? Yuhan’s Latest Trial Update Is Turning Heads

Yuhan Corp's YH35995 shows promising results for Gaucher disease in Phase 1 trial, demonstrating long-lasting efficacy and BBB penetration.

North Korea Says It Beat the U.S. Once—And Could Do It Again

North Korea intensifies anti-American rhetoric ahead of Victory Day, claiming victory in the Korean War and asserting its nuclear strength.

How Celltrion’s Local Production Strategy Eliminates U.S. Drug Tariffs Influence

Celltrion resolves tariff impacts on U.S. sales, boosting local production and growth opportunities for its biosimilars, including Zymfentra.

Tag: MSCI index inclusion

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

No posts to display

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.